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Minardi et al1 have described well-established risk factors for recurrent urinary tract 
infection (UTI) and have emphasized the importance of a clear communication with 
the patient in order to find out behavior at risk, channel right hygiene recommendations, 
and suggest necessary changes in life habits to prevent acute UTI episodes. There is 
general agreement that behavioral modifications and counseling should be attempted 
first to reduce the rate of acute UTI episodes and their associated discomfort.
Furthermore, the authors mentioned the guidelines of the European Association 
of Urology2 for the treatment of acute infections and the prophylaxis of recurrences. 
In particular, they referred to the standard antimicrobial prophylaxis (continuous, 
intermittent, and postintercourse) and mentioned some alternative strategies as well. 
Unfortunately, no further details were provided on immunoactive prophylaxis, the most 
developed alternative to antibiotics for the prevention of recurrent UTI.
Among the products on the market, Uro-Vaxom® (UV) (OM Pharma SA, Geneva, 
Switzerland), a lyophilized lysate of 18 bacterial Escherichia coli strains, is at pres-
ent the only prophylactic alternative to antibiotics recommended with a grade “B” by 
the European Association of Urology guidelines because of its good clinical efficacy 
established with a high level of evidence (1A) in two published meta-analyses of ran-
domized placebo-controlled studies.3,4 A grade of  “C” or “D” (no recommendation 
possible) was assigned to all other alternatives, including products of the same class 
and others such as cranberry or probiotics, due to the small number of weak clinical 
studies or conflicting results.
Naber et al’s meta-analysis4 was performed on five published randomized placebo-
controlled studies with UV (OM-89), including a total of 1000 adult patients with an 
observation period of 6–12 months.5–9 There was a significant reduction in mean num-
ber of UTI episodes as percentage of placebo by –35.7% at 6 months and by –39.4%, 
including the value, at 12 months. The studies with the largest number of UTIs with 
placebo showed also the largest reduction of UTI events with UV . Significantly, more 
patients in the active group, compared with placebo, were free of any UTI episode at 
the end of the studies, regardless of the study duration (P = 0.001). As the number of 
UTIs was lower in UV-treated patients compared with placebo, there was a parallel 
reduction of antibacterial consumption with a standardized mean difference of –0.29 
(95% confidence interval, -0.44; -0.14).
The pooled data also confirmed the good risk–benefit profile of UV . The differ-





slightly more frequent in UV-treated patients than in placebo 
(+0.8%). No serious adverse events were attributed to UV in 
these clinical studies and no disease- or age-related mortality 
was recorded in the investigated population.
UV was registered a long time ago in Switzerland and 
Germany (1987) and it can be prescribed for prevention of 
recurrent UTI in more than 50 countries worldwide. Unfor-
tunately, UV is not available in Italy, which may have been 
the reason why Minardi et al did not mention it. However, 
since the review was published in an international journal, 
readers should also be informed about the immunoactive 
prophylaxis of recurrent UTI with UV, a well-established 
and internationally recommended drug for the prevention of 
recurrent UTI. According to pharmacovigilance data, UV is 
a well-tolerated product (overall incidence of side effects, 
4%) that can be administered in adults and children over 4 
years old.10 New clinical studies are ongoing in order to better 
understand its mechanism of action, to confirm its long-term 
efficacy, and to explore new indications.
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adequate information on the most recent advances on the 
application of immune prophylaxis (although it cannot be 
used in all countries) in the European Association of Urol-
ogy guidelines.1
Currently, immune active prophylaxis is in use in many 
countries. However, its mechanisms of action and long-term 
efficacy are still under investigation. Therefore, neither this 
therapy, although interesting and promising, nor the drug 
Uro-Vaxom® (OM Pharma SA, Geneva, Switzerland), have 
been considered in our review, although we have provided 
some general references on experimental technologies and 
research on the immune response and the opportunity for the 
development of such vaccines.
Since the use of immune prophylaxis has been widely 
treated in the European Association of Urology guidelines,1 
we do not find that omitting a specific product from our 
review should deprive the reader interested in the treat-
ment of urinary tract infections in their own research on 
this area.
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The main aim of our paper was to review generally the current 
options and technologies available for treatment of urinary 
tract infections. The different classes of antibiotic have been 
cited in general, without entering into details about the use 
of individual antibiotics or their dosages. References con-
cerning practical guidelines have been given for the reader 
to find more detailed information. It is also possible to find 